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Long-term oral vitamin E supplementation in cystic fibrosis 
patients: flftft-a-tocopherol compared with all-rac-a- 
tocopheryl acetate preparations1-3
Brigitte M Wiuklhofer-Rooh, Martin A van 7 Hof, and David H Shmerling
ABSTRACT 'To investigate the efficacy of three different 
vitamin E preparations for optimizing vitamin E status in cystic 
fibrosis (CF) patients long-term, 29 patients (aged 0.7-29.8 y) 
were randomly assigned to receive 400 IU of either RRR-cx- 
toeupherol ( A: 268 mg, n — 10) or all-mr-it-toeopheryl acetate as 
a fat-soluble (.13: 400 mg, n = 10) or waler-miscible preparation 
(C: 400 mg, n = 9) and were followed for 6 wk. In the whole study 
group, plasma cv-tocopherol concentrations increased from base­
line (10.5 ± 4.6 fxmol/L) to 3 wk (25.7 ± 6.5 /xmol/L; P < 0.001), 
but not further between 3 and 6 wk; concentrations at 3 and 6 wk 
did not differ from those of age-matched control subjects (23.6 ± 
3.9 jLtmol/L). There was no significant difference in the increase 
from baseline to 6 wk among preparations A (17.75 ± 8.43 
fxmol/L), B (14.0 ± 9.4 fxmol/L), and C (15.5 ± 7.1 /¿mol/L). 
Because of differences in body weight, the dose administered 
ranged from 5.5 to 47.4 IU•kg" 1 ‘ d"1; it correlated positively 
with the increase in plasma cv-tocopherol concentrations (P <
0.001). There was no significant difference in the increase in 
plasma «-tocopherol concentrations between patients with CF- 
associated liver tlisease (// ™ 8) who received 10.2 ± 3.8 
IU * kg 1 • d 1 and those without liver disease taking comparable 
doses. We conclude that CF patients cun be efficiently supple­
mented with 400 lU/d of any one of the three vitamin E prepara­
tions and plasma values of healthy control subjects can be 
achieved. Am J Clin Nutr 1996;63:722-8.
KEY WORDS All-re/r-iv-loeopheryl acetate, cystic fibro­
sis, liver disease, long-term supplementation, AV^ -a-tocoph- 
erol, waler-miseible vitamin H
INTRODUCTION
Cystic fibrosis (CF) patients, who in 85.90% of cases have
exocrine pancreatic insufficiency (I), frequently exhibit bio­
chemical vitamin E deficiency even when taking pancreatic 
en/.yme replacement therapy (2-4). Therefore, long-term oral 
supplementation has become part of the routine therapeutic 
regimen (5, 6)* However, even though CF patients efficiently 
absorb a single oral dose of 100 mg all-/w-cv-tocopheryi ace- 
tate/kg body wt (7, 8), 10-20% were shown to remain vitamin 
E deficient long-term (9, 10). In other studies, plasma cv-to- 
copherol concentrations achieved in CF patients were not dif­
ferent from those of control subjects (2, 3, 11-13), but were 
considerably lower than plasma «-tocopherol concentrations
published more recently for healthy individuals from different 
populations (14-16),
One decade ago the goal of vitamin E supplementation in CF 
patients was to prevent neurologic dysfunction, the clinical 
manifestation of vitamin E deficiency (3). Since then, evidence 
has accumulated that suboptimal vitamin E status is biologi­
cally relevant (17-20). Epidemiologic data document that 
plasma cv-tocopherol concentrations of 26-28 \xmol/L are as­
sociated with a decreased risk of mortality from ischemic heart 
disease (20), whereas lower concentrations, though still above 
the lower limit of normal, do not appear to exert a protective 
effect. In a comparison of two populations with plasma «-to­
copherol concentrations of 25 ± 4 and 29 ± 5 /umol/L, the one 
with lower plasma cv-tocopherol values showed significantly 
higher values for different indexes of lipid peroxidation (14). 
Supplementation with vitamin E in healthy subjects with base­
line plasma cv-tocopherol concentrations of 23 ± 4 /nmol/L 
decreased susceptibility of low-density lipoprotein (LDL) to 
oxidative stress (15). Given the oxidant-antioxidant imbalance 
in favor of oxidation due to chronic lung inflammation on one 
hand, combined antioxidant deficiencies on the other (21), and 
evidence of increased oxidative damage (22), efficient anti ox­
idant protection seems to be crucially important in CF patients, 
Biochemical vitamin E deficiency in CF patients is associated 
with impaired resistance of LDL to in vitro oxidative stress; 
improvement of vitamin E status fully reverses it to normal 
(16). There is preliminary evidence that optimization of anti­
oxidant status might ameliorate chronic pulmonary inflamma­
tion in these patients (23). Supplementation with polyunsatu­
rated fatty acids (PUFAs) is being considered to both correct 
biochemical essential fatty acid deficiency (with linoleic acid;
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24, 25) and reduce pulmonary inflammation (with n — 3 fatty 
acids; 26, 27). This intervention may result in increased vita- 
min E demands, as suggested by a close inverse correlation 
between LDL resistance to oxidation and linoleic and arachi- 
clonic acid contents (16), Because of these new data, this study 
focuses on vitamin E supplementation in CF patients to achieve 
vitamin E status well above the lower limit of normal for 
healthy individuals of the same population.
SUBJECTS AND METHODS
Thirty-one CF patients (18 males, 13 females ) aged 0.7-29.8 
y (median 6.9 y) with exocrine pancreatic insufficiency, who 
were under long-term care at our CF outpatient clinic and had 
plasma cv-tocopherol concentrations below the l()th percentile 
of control subjects of the same age range (19.5 /¿mol/L) were 
enrolled. All took pancreatic enzy mes—Pro lipase (Cilag AG 
Pharma Schweiz, Schaffhausen, Switzerland), Creon (Kali- 
Duphar Pharma, Bern, Switzerland), and Panzytmt 25.000 
(Knoll AG, Liestal, Switzerland)—in doses adjusted individu­
ally to the results of repeated fat-balanee studies (28). The 
actual mean coefficient of fat absorption (CFA) was 81 ± 11%. 
Nine patients had been taking 100 0? = 4) or 200 (n ™ 5) IU id 
(100 or 200 mg/d, respectively) of oral all-/m-a-tocopheryÍ 
acetate long-term before this study, but had not achieved nor­
mal vitamin E status. At study entry, patients were screened for 
the absence or presence of CF-assodated liver disease (LD) by 
sonographic (hepatomegaly, grossly granular or nodular struc­
ture, portal hypertension, splenomegaly) and laboratory criteria 
(y-glutamyltransferase, alkaline phosphatase, total serum bile 
acids). Eight patients had LD on the basis of the following 
laboratory test results (median, range): y-glutamyltransferase 
activity (0.86, 0.27-2.86 jukat/L); alkaline phosphatase activity 
(14.49, 4.79-32.31 /¿kat/L); and total serum bile acid concen­
tration (3.85, (M2.8 /¿mol/L).
Tweniy-nine control subjects (12 males, 17 females), 
matched with CF patients for age (± 3 mo), served as refer­
ences for plasma «-tocopherol concentrations of patients after 
6 wk of treatment. They were either attending the hospital for 
constitutional short stature, minor surgery, or ear, nose, and 
throat problems and were not taking drugs that affect fat or 
vitamin absorption, or they were healthy nonsmoking staff 
members who consumed an average diet and were not taking 
vitamin supplements. The study protocol was approved by the 
Ethics Committee of the Department of Pediatrics, University 
of Zurich, and informed consent was obtained from the patients 
or their parents.
Therapeutic intervention
Patients were randomly assigned to receive daily 400 ÍU 
(268 mg) /MV^a-loeopherai (preparation A, Mullaben; Roche 
Pharma Schweiz, Reinaeh, Switzerland) or 400 IU (400 mg) 
all-Mr-«-loeopheryl acetate, either in a fat-soluble (preparation 
B, Ephynal; F Hoffmann-La Roche AG, Basel, Switzerland) or 
waler-miscible form (preparation C, E-Vimin; Astra
Liikemedel AB, Soderltiljc, Sweden, which contains Polysor- 
bate 80 as an emulsifier). This dose was chosen becuu.se 
long-term supplementation with 100-200 IU alUmr-«-toeoph- 
eryl acetate/d had not corrected low plasma «-tocopherol con-
eentrations in a substantial proportion of CF patients before this 
study (unpublished data). Comparable doses on an IU/d basis 
were used to account for differences in biological activity 
between the RRR- and all -rucemic form of a-to cop h crol (sev 
Appendix A). Preparations A and C were gelatin capsules and 
preparation B was a ehcwable tablet. Each capsule of prepara­
tion A contained 400 IU, whereas those of preparations B and 
C contained 100 IU of the vitamin; thus, patients took one 
capsule or tablet daily of preparation A and four of preparations 
B and C, respectively. Because the capsules and tablets could 
not be divided, dose administration was not adjusted to indi­
vidual body weight. Body weight ranged from 8.4 to 72,9 kg; 
therefore, the dose per kilogram ranged from 5.5 to 47.7 
IU • kg 1 * d l. Patients took the vitamin together with pancre­
atic enzymes at breakfast. Two infants had the content of the 
gelatin capsules placed into their mouths by their mothers. 
Compliance was monitored by asking patients and parents if 
any capsules had been missed and by checking the quantities of 
capsules supplied. All preparations were given to the patients 
in similar bottles and plasma samples from study patients were 
not indicated as such and were delivered to the laboratory 
together with those of patients not enrolled in the study. Mea­
surement data were analyzed blind by using codes for the
d i ffe re nt preparado n s,
Assessment of treatment efficacy
The study protocol included three evaluations (study entry, 
and 3 and 6 wk) to provide information about the increase and 
a possible plateau effect in plasma «-tocopherol concentra­
tions, and, in addition, in ratios of plasma «-tocopherol to 
cholesterol, while limiting the number of venipunctures to a 
minimum. Blood was drawn after an overnight fast and plasma
was separated and kept a t..20 °C for a maximum of 4 d before
plasma «-tocopherol concentrations were determined by HPLC 
(29) in the laboratories of the Division of Vitamin Research of 
F HolTmann-La Roche. Plasma cholesterol concentrations were 
determined enzymatically with a kit from Beckman Ltd, Brea, 
CA, To correct for differences in plasma cholesterol concen­
trations among study patients and between patients and control 
subjects, ratios of plasma «-tocopherol to cholesterol were 
calculated (30).
Staii.siJcnl analysis
Paired t tests were applied for comparison of plasma («“to­
copherol concentrations in patients between baseline and 6 wk 
of treatment, two-sample / tests for comparisons between pa­
tients and age-mate bed control subjects, and between patients 
will) and without LD, One-way analysis of variance (ANOVA) 
with Tukey’s range test was used for comparison of the in­
crease in plasma «-tocopherol concentrations among the three 
preparation groups (with dose/kg included as a covariate) and 
of patient characteristics. Pearson's correlation was applied for 
the relation between the increase in plasma «-tocopherol con­
centrations and the dose/kg body wt. STATGRAPHICS (ver­
sion 6; STS(\ Inc, Rockville, MD) was used for statistical 
procedures, Results are expressed as mean 
were considered significant at P < 0.05.
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RESULTS 
Study groups
Two patients dropped out because of m>ncompliance; 29 
patients completed the study: 10 received preparation A, 10 
preparation B, and 9 preparation C. Subject characteristics of 
(lie three groups are presented in Tabic 1. There were no 
significant differences in CFA or dose/kg body wt. Plasma 
cholesterol concentrations were lower in patients taking prep­
arations B and C than in those taking preparation A (ANOVA, 
Tukey’s range test)«
Treatment efficacy
Vitamin E was well-tolerated without evidence of any side 
effects* In the whole study patients plasma a-tocopherol con­
centrations increased between baseline and 3 wk, but not 
further between 3 and 6 wk (Table 2); at 6 wk they did not 
differ significantly from those of age-matched control subjects. 
Plasma «-tocopherol concentrations at 6 wk were below the 
3rd percentile of control subjects (17.28 /xmol/L) in three 
patients (10.8, 15.6, and 15.6 /xniol/L), two of whom had had 
normal concentrations at 3 wk. Plasma «-tocopherol concen­
trations at 6 wk were above the 97th percentile of control 
subjects (30.0 /¿mol/L) in two patients (40,2 and 41.6 jtxmol/L). 
Ratios of plasma a-tocopherol to cholesterol increased accord­
ingly and were significantly higher in patients at 6 wk than in 
control subjects (P <  0.0001) (Table 2). This can be explained 
by lower plasma cholesterol concentrations of patients com­
pared with control subjects (P <  0.0001)*
The increase in plasma a-tocopherol concentrations and 
ratios of plasma a-tocopherol to cholesterol from baseline to 6 
wk did not differ among the three preparation groups (Table 
3). There was a positive correlation between the increase in 
plasma a-tocopherol concentrations and the dose/kg body wt 
(P = 0.0006) (Figure 1), but dose/kg did not differ among the 
preparation groups.
Liver disease
Because there was a significant age difference between pa­
tients with and without LD (with LD: 14.5 ± 4.7 y; without
LD: 8.4 ± 8.8 y) and, consequently, in body weight and 
do sc/kg, further comparison between these two groups was 
performed only in patients receiving comparable doses/kg (// = 
8 each, 10.2 ± 3.8 compared with 10,5 ± 4.4 1U • kg"'1 * d l). 
The ratio of the number of patients taking preparations A:B;C 
was 3:3:2 in those with LD and 1:3:4 in those without. CFA 
(with LD: 79.6 ± 9.8%; without LD: 80.9 ± 12.6%) and 
plasma cholesterol concentrations (with LD: 3.60 ± 0.70 
mmol/L; without LD: 3.31 ± 0.58 mmol/L) did not differ 
significantly between the two groups. There was no significant 
difference in the increase in plasma a-tocopherol concentra­
tions and ratios of plasma a-tocopherol to cholesterol. Only 
ratios of plasma a-tocopherol to cholesterol at 6 wk (which 
were lower at baseline in patients with LD) remained lower in 
patients with LD compared with those without (Table 4).
DISCUSSION
As outlined above, we considered the overall goal of vitamin 
E supplementation in CF patients to be to achieve plasma 
a-tocopherol concentrations well above the lower limit of 
normal, and thus ensure efficient protection against free radi­
cal-induced tissue damage. Therefore, patients who had not 
reached plasma a-tocopheroJ concentrations above the 10th 
percentile of age-matched control subjects before this study 
were considered candidates for improvement of vitamin E 
status. After 3 wk of treatment, the vitamin E status of patients 
was comparable with that of the age-matched control subjects, 
which was also comparable with that of the general Swiss 
population (29). In contrast, healthy subjects from other pop­
ulations had considerably lower plasma a-tocopherol concen­
trations (2-4, 31). A further increase was not observed between 
3 and 6 wk, indicating that a steady state had been reached at 
or before 3 wk of treatment, which is compatible with plateaus 
reached between 3 d and 2 wk reported for healthy subjects 
(32-34). Three patients had plasma a-tocopherol concentra­
tions below the 3rd percentile at 6 wk, two of whom had shown 
normal values at 3 wk; this most likely indicates a drop in 
compliance after 3 wk. The lack of a significant difference in
TABLE 1
Patient ehuniclerisiies of the groups assigned the three preparations
Age* (y)
Weight (kg)
CFA
Plasma cholesterol (mmol/L) 
Liver disease 00 
Pretreated 00
OU • kg
(IlJ/cl)
(mg/d)
J M i
1 ,v ± SIX 
'■ Coefficient of Hit absorption.
i r r u i r “  fit <fh n i JVVi
bJOVJ Ú9Q. t I > j- IfM  ¿UftMMmAáa to* ** ^« ria  «4 *+* w«
A, A7\7\*-íí-tneopherol 
(// 6M» 4l;)
mu
7.0 i
21.7 :i; 14.4 
:!: I 1.0
3.61 1.33
3
0
82.5
25.5 ± 13.L* 
400 
268
*****
Preparation
....... . ii w  i rm  ii i ■ ....i^ * _  ........ ¡ . u  . v | r r ^
All-/v/t tocophcryl acetate
H, ftti-sokible 
(/{ - ■ fvM, 410
10.7 ü: 7.0 
34.0 ±21.2
83.8 13.3 
3.31 ± 0.52'*
3
3
17.3 ±  I l . l 1 
400 
400
% M I V  1 W I M ^ 1 * 1 1  I I I M J I M  I  M
'Not significantly different among pie pa rat ions (ANOVA, Tu key’s range test).
'* Significantly difiereut from preparation A, P < 0.05. (ANOVA, Tukcy*s range test).
C, waier-miscihle
(n 4M, 51’)
12.« ± l).7 
34.« ± 20,«
77.(1 ± K.2 
3.14 ± 0.42''
4
17.5 12..V 
400 
400
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TABLK2
Response of (he whole study group to 400 IU vitamin H/d and comparison of plasma 
the same population7
values al 6 wk with those of agc-nuUelietl control subjects from
Patients Control subjects
Baseline 3 wk 6 wk
Plasma «-tocopherol (/xmol/L)
Ratio of plasma «-tocopherol to cholesterol (mmol/mol) 
Plasma cholesterol (mmol/L)
10.5 *  4.6 
3.06 1.30 
3.47 ± 0.60
25.7 ± 6.5 
7.93 1: 2.05 
3.29 ± 0.57
26.2 :t ().K-! 
7.92 ± 1 .X8-- 
3.34 0.60
23.6 t  3.9 
5.66 i  1.1K1 
4.27 :t 0.80'
1 x ±  SD; n ~ 29 subjects per group.
“’ Significantly different from baseline, P <  O.OOOl (paired ( test).
J Significantly different JVom patients ut 6 wk, P <  O.OOOl (two-sample ( test).
the improvement of vitamin E .status between patients with and 
without associated LD is in line with data of Stead et, al (3), and 
suggests that the requirement of intraluminal bile acids for 
efficient vitamin E absorption was met in these patients.
To our knowledge, this is the first study showing a complete 
normalization of vitamin E status in CP patients, with plasma 
«-tocopherol concentrations of 26,2 ± 6.8 /xmol/L. The im­
portance of achieving plasma a-tocopherol concent rations this 
high is underlined by recent findings, in CF patients, median 
plasma «-tocopherol concentrations of 14.8 ¿xmol/L were ac­
companied by increased lipid peroxidation (22); the increase in 
plasma «-tocopherol concentrations from 9.0 ± 4.2 to 27.8 ± 
8,1 /imol/L (ratios of plasma a-tocopherol to cholesterol from 
3.3 ± 1.8 to 9.9 ± 2.6 mmol/mol) was associated with a full 
reversion of impaired resistance to in vitro oxidative stress of 
PUFAs in LDL (J6); only a further increase in plasma a- 
toeopherol concentrations from 28.3 ± 9.3 to 35.3 ± 9.5 
/xmoI/L was associated with a decrease in lipid peroxidation 
(35). On the basis of the observation that increased suscepti­
bility to peroxide-induced hemolysis occurs in CF patients with 
vitamin E status comparable with that of healthy control sub­
jects of the same age range, James et al (31) proposed that a 
ratio of plasma «-tocopherol to cholesterol > 4.8 mmol/mol is 
necessary to protect against peroxidative damage.
TABU«: 3
Hffeet of supplementation on plasma or-tocopherol concentrations and
ratios of plasma «-tocopherol to cholesterol in the three groups*
Preparation
A (/! ~ 10) li t/i ^  10)
^  r  . V .  |J f  ^ M M l  11
(• (II 9)
Plasma cHocophcro] (/¿mol/L)
■» *■ al^t> rii<V WM"t’I^ “ V“ ^■ Qp Wi1 v  ^V ^ W  ^ M * IS® *^  T f ^ v 1^ ♦
Baseline 10.7 5.1 10.8 *; 4.9 9.9 ± 4.2
3 wk 27.« it 6.0 23.5 ±  7.1 25.6 0.3
6 wk 28.4 5.5 24.9 ± 8.4 25.4 * 6.4
Increase from baseline to
6 wk 17.7 ±: 8.4 14.0 ± 9.4 15.5 ± 7.1
Ratio of plasma «-tocopherol
to cholesterol (mmol/mol)
Baseline 2.89 ± 1.64 3.17 ± 1.16 3.13 1.16
3 wk 7.97 ± 2.28 7.27 ± 1.94 8.61 ± 1.90
6 wk 7.88 ± 1.80 7.60 ± 1.58 8.3 1 ± 2.36
Increase from baseline to
6 wk 4.99 1.49 4.43 ± 1.77 5.19 ' 2.38
in
p p ^ ~ fl ................  |  » « " ~ |  W  -------------------  T -  — - -
soluble; C, all-wr-a-Locopheryl neetute, wator-mi.scible, There were no 
significant differences among groups for the increase from baseline to 6 wk 
for cilher measure (by ANOVA with Tukey’.s range test).
The natural source of a-tocopherol, the AVM-enantiomer, is 
known to be a more biologically active form than the synthetic 
nU-nwtwih' «-tocopherol, The relative activity of RRR-a- 
tocopherol is 1.36 times the activity of ull-n/e-«-toeapheroi 
and 1.49 times that of aJl-mwv-tocopheryl acetate, as derived 
from animal bioassays such as the resorplion-gestation test in 
rats (36). Even though this re Union might be a function of 
bioavailability, it does not necessarily apply to humans. How­
ever, in a single-dose study in humans, the area under the 
concentration time curve from 0 to 96 h was 1.5-fold higher 
for/?/?/?- than for all-motv-toeopherol (37), in previous studies 
(33, 38), and in the present investigation, this difference was 
taken into account by using comparable doses on an IU basis 
(see Appendix A).
All-wr-a-toeopherol is a mixture of eight stereoisomers, 
one-eighth of which i.s the RRR-fovm. Compared with the 
SRR-tbrm, it is equally well absorbed but preferentially taken 
up by very-low-density lipoprotein (VLI)L) and .secreted into 
the plasma (39); a hepatic tocopherol-transfer protein is 
thought to be responsible for (his selectivity (40, 41). One-half 
of the isomers from the all-ntcvmic preparation (with .V-con­
figuration at C2) are probably not recognized by the hepatic 
loenpheroLttunsfer protein. This is based on studies in humans 
receiving single pharmacologic doses of dcuteraled «-tocoph­
erol (39, 40). From these studies, a rate of • 74 juunol/d was 
estimated for /?/?/?-«-tocopherol resecretion into the plasma 
(42).
In this study, no differences were observed in the efficacy of 
400 RJ/d RRR- compared with the all-/Y/mwV forms for in­
creasing plasma os-tocopherol concentrations. This agrees with 
another long-term supplementation study (hat gave K00 IIJ (536
<10 • • • •  - •  •
p-J
»«S io •m
e
h U
= t
• w -
J—
20< »
ctf m
& < •i
</) <
a) 10 i  f4
a. 0* *
< + * ♦
0 . t  •  . *  * *  :  i 1  e
t} 10
D
t, TIm increase (
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t mi mi
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30 40 liO
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between baseline and 6 wk of .supplementation is plotted against the daily 
dose/kg body wl There was a significant correlation between dose/kg and 
the increase in plasma ^-tocopherol concentrations.
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TABLE 4
Comparison of the response to vitamin E supplementation between 
patients with and without liver disease (LI>) who were taking 
compara hie doses'
With LD 
(// — 8)
Without LD 
(n «  8)
Plasma a-tocopherol (,/u.mol/L)
Baseline 10.4 :£ 4.1 14.5 ±3,7
6 wk 20.9 ± 5.3 27.4 ± 7.3
Change 10.5 ± 5.» 12.9 ±9.1
Ratio of plasma «-tocopherol 
to cholesterol (mmol/mol)
Baseline 3.02 ± 1.29 4.35 ± 0.84"
6 wk 6.35 ± 1.65 9,34 ± 2.02-?
Change 3.34 ± 1.49 4.99 ± 2.1 1
Plasma cholesterol (mmot/L)
Baseline 3,60 ± 0.70 3.31 ± 0.58
ft wk 3.34 0.72 2.96 ±0.61
Change -0.26 & 0.15 — 0.35 ±0.74
* x ± 5>D. Patients with LD were taking 10.2 ± 3.8 Ili * kg 1 ♦ cl l; 
patients without LD were taking 10.5 ± 4,4 IU • kg 1 • d 1 (NS),
Significantly different from patients with LD (two-sample t test): 
2 F < 0.05, J P <  0.0 L
mg) RRR- and all-rac-a-tocophery I acetate (BOO mg)/d to 
healthy subjects (33). In contrast, simultaneous ingestion, of 
150 mg/d of both deuterated RRR-cl-tocopheryI acetate (d3, 
204 IU/d) and all-zY/ooi-tocophcryl acetate (d6, 150 IU/cI) 
over 11 d showed areas under the curve for plasma a-to­
copherol concentrations almost twice as high for the RRR- as 
for the a ll-racem ic form (43). Given a 50-80% fractional 
absorption of vitamin E in healthy subjects (44) and the 
average CFA of 83% in the study patients, it is very likely 
that < 50% was absorbed in. this study. Nevertheless, the 
daily amount of RRR-cx-tocopherol absorbed might have 
exceeded the capacity for resecretion into the plasma. It 
cannot be ruled out that a greater bioavailability of the 
RRR-i'orm than that adjusted for with dosing on a IU basis is 
alleviated when high doses of the vitamin are given daily. 
On the other hand, simultaneous ingestion of two forms 
could result in competition for receptors, in contrast with 
ingestion of a single preparation.
Both preparations B and C were nll-m*-«-tocophery I ac­
etate, an esterified form of a-tocopherol. Hydrolysis of the 
ester bond by pancreatic esterases is proposed to be impor­
tant and rate-limiting, but may not be obligatory for absorp­
tion (45). CF patients may lack these esterases because of 
their exocrine pancreatic insufficiency, and it is uncertain if 
pancreatic enzyme supplements or esterases from cntero- 
cytes (45) compensate for this deficiency. The results of this 
study suggest that the ester bond was readily hydrolyzed 
because differences were not observed between the free and 
esterified a-tocopherol. This is in line with data on healthy 
subjects (46).
Water-miscible preparations contain an emulsifier to facili­
tate solubilization and enhance intestinal absorption in cases of 
fat malabsorption. Whereas in one study of CF patients equal 
doses (10 nig/kg) of water-miscible all-me-a-tocopheryl ace­
tate led to higher plasma «-tocopherol concentrations than did 
fat-soluble all-mc-a'-toeopheryl acetate (12), no such differ­
ence was observed in this study. When doses in a 1:4 relation
were given in another study (200 IU water-miscible prepara­
tion, not further specified, «-tocophery 1 acetate and 800 IU 
fat-soluble RRR-ot- tocophery I acetate), no differences were 
seen, perhaps indicating greater bioavailability of the water- 
miscible preparation (13).
As noted, the dose given to individual patients was not 
adjusted to body weight in this study. A positive correlation 
between the increase in plasma a-tocopherol concentrations 
and the dose/kg was found in our study, in contrast with a 
lack of dose-response relation in healthy subjects in other 
studies who received doses as high as 440-1320 (32) or 
1000-3000 IU/d (34). This relation did not affect the re­
sponse to the three different preparations because dose/kg 
did not differ among the three groups. As can be seen in 
Figure 1, this correlation was not close enough to allow 
conclusions about the appropriate dose/kg for optimizing 
vitamin E status in virtually all CF patients. Recently, 5-10 
IU (5-10 mg) all-/Y/oa~tocopheryl acetate * kg 1 * d 1 did 
not correct vitamin E deficiency in 10% of infants with CF 
(9). In contrast, the authors of another study (3) concluded 
that CF patients, except those with severe LD, do not require 
>10 mg all-/m’-a-tocophery I acetate ■ kg”"1 • c l 1. How­
ever, after 1 mo with this dose, two of four of their patients 
with LD and two of four without LD still had plasma 
a-tocopherol concentrations below the 10th percentile of 
control subjects in the present study, as did three of four 
patients in both groups after 1-3 mo of 200 mg/d. In our 
study, all four patients without LD taking < 10 lU/kg (but a 
total of 400 IU/d) and four of five patients with LD taking 
a similar dose, achieved plasma a-tocopherol concentrations 
above the 10th percentile of control subjects, whereas other 
patients (with and without LD) taking > 10 IU/kg (but also 
a total of 400 IU/d) did not reach these concentrations. 
These data either confirm the well-known substantial inter­
individual variability in the response to vitamin E intake in 
humans or reflect variable compliance.
In conclusion, to ensure optimal vitamin E status in prac­
tically all CF patients, we recommend supplementation with 
a daily dose of 400 IU, irrespective of the a-tocopherol 
preparation used. However, not all patients will require 400 
IU/d. Even in view of the broad therapeutic range of vitamin 
E (47), preparations with different doses are needed to allow 
differentiated adjustment of the dose for the individual 
palient. This approach, however, requires patients to attend 
CF care centers where careful monitoring of treatment effi­
cacy can be offered. 13
Wc acknowledge the determinations of plasma «-tocopherol concentra­
tions in the laboratories of the Division of Vitamin Research of 1; Hoff­
mann Lu-Roohe AG, Basel, Switzerland.
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APPENDIX A
Vitamin E: form, activity, and mg substance
lU/m g 
substance
Conversion from mg 
substance to mg
a-TE
fl/iR-a-tocopherol 1.49 1.00
A'AVv*-a-tocophcryl acetate 1.36 0.91
all-rm’-iv-tocopherol 1.10 0.74
all-wc’-w-toeopheryl aeetalc 1.00 0.67
The international unit (IU) of vitamin E, which is numerically equal to 
the USP unit, is still used in labeling of vitamin E preparations, but should 
be replaced by mg substance and «-tocopherol equivalents C«-TE).
